Arizona State Retirement System Purchases New Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

Arizona State Retirement System purchased a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGXGet Rating) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,667 shares of the company’s stock, valued at approximately $99,000.

Other large investors have also made changes to their positions in the company. Royal Bank of Canada acquired a new stake in shares of Tango Therapeutics in the first quarter valued at $32,000. Teacher Retirement System of Texas purchased a new stake in shares of Tango Therapeutics during the 3rd quarter worth approximately $36,000. Renaissance Technologies LLC purchased a new stake in Tango Therapeutics in the 3rd quarter valued at approximately $41,000. Jump Financial LLC purchased a new stake in Tango Therapeutics in the 3rd quarter valued at approximately $49,000. Finally, Occudo Quantitative Strategies LP acquired a new position in Tango Therapeutics in the 2nd quarter valued at $50,000. 77.30% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upped their price objective on Tango Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, March 28th.

Tango Therapeutics Trading Down 16.6 %

Shares of NASDAQ:TNGX opened at $2.92 on Friday. Tango Therapeutics, Inc. has a 52 week low of $2.88 and a 52 week high of $8.56. The firm has a market capitalization of $258.16 million, a P/E ratio of -2.32 and a beta of 1.62. The firm’s 50 day moving average is $3.84 and its two-hundred day moving average is $5.79.

Tango Therapeutics (NASDAQ:TNGXGet Rating) last issued its earnings results on Tuesday, May 9th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04. Tango Therapeutics had a negative net margin of 446.26% and a negative return on equity of 42.34%. The firm had revenue of $5.77 million during the quarter, compared to analysts’ expectations of $6.70 million. Analysts predict that Tango Therapeutics, Inc. will post -1.4 EPS for the current year.

Tango Therapeutics Profile

(Get Rating)

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.

Featured Stories

Want to see what other hedge funds are holding TNGX? Visit to get the latest 13F filings and insider trades for Tango Therapeutics, Inc. (NASDAQ:TNGXGet Rating).

Institutional Ownership by Quarter for Tango Therapeutics (NASDAQ:TNGX)

Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with's FREE daily email newsletter.